Yao Min, Lu Xin, Lei Yingfeng, Yang Jing, Zhao Haiwei, Qiao Qinghua, Han Peijun, Xu Zhikai, Yin Wen
Department of Microbiology, Fourth Military Medical University, Xi'an, China.
Department of Blood Transfusion, Xijng Hospital, Fourth Military Medical University, Xi'an, China.
PLoS One. 2016 Mar 4;11(3):e0150894. doi: 10.1371/journal.pone.0150894. eCollection 2016.
Hepatitis C virus (HCV) frequently establishes persistent infections that can develop into severe liver disease. The HCV NS3/4A serine protease is not only essential for viral replication but also cleaves multiple cellular targets that block downstream interferon activation. Therefore, NS3/4A is an ideal target for the development of anti-HCV drugs and inhibitors. In the current study, we generated a novel NS3/4A/Lap/LC-1 triple-transgenic mouse model that can be used to evaluate and screen NS3/4A protease inhibitors. The NS3/4A protease could be conditionally inducibly expressed in the livers of the triple-transgenic mice using a dual Tet-On and Cre/loxP system. In this system, doxycycline (Dox) induction resulted in the secretion of Gaussia luciferase (Gluc) into the blood, and this secretion was dependent on NS3/4A protease-mediated cleavage at the 4B5A junction. Accordingly, NS3/4A protease activity could be quickly assessed in real time simply by monitoring Gluc activity in plasma. The results from such monitoring showed a 70-fold increase in Gluc activity levels in plasma samples collected from the triple-transgenic mice after Dox induction. Additionally, this enhanced plasma Gluc activity was well correlated with the induction of NS3/4A protease expression in the liver. Following oral administration of the commercial NS3/4A-specific inhibitors telaprevir and boceprevir, plasma Gluc activity was reduced by 50% and 65%, respectively. Overall, our novel transgenic mouse model offers a rapid real-time method to evaluate and screen potential NS3/4A protease inhibitors.
丙型肝炎病毒(HCV)常常会引发持续性感染,进而发展为严重的肝脏疾病。HCV NS3/4A丝氨酸蛋白酶不仅对病毒复制至关重要,还能切割多个阻碍下游干扰素激活的细胞靶点。因此,NS3/4A是开发抗HCV药物和抑制剂的理想靶点。在本研究中,我们构建了一种新型的NS3/4A/Lap/LC-1三转基因小鼠模型,可用于评估和筛选NS3/4A蛋白酶抑制剂。利用双Tet-On和Cre/loxP系统,NS3/4A蛋白酶可在三转基因小鼠的肝脏中实现条件性诱导表达。在该系统中,强力霉素(Dox)诱导会导致高斯荧光素酶(Gluc)分泌到血液中,且这种分泌依赖于NS3/4A蛋白酶在4B5A连接处的切割作用。相应地,仅通过监测血浆中的Gluc活性,就能快速实时评估NS3/4A蛋白酶活性。这种监测结果显示,Dox诱导后,从三转基因小鼠采集的血浆样本中Gluc活性水平增加了70倍。此外,血浆中增强的Gluc活性与肝脏中NS3/4A蛋白酶表达的诱导密切相关。口服商用NS3/4A特异性抑制剂特拉匹韦和波西普韦后,血浆Gluc活性分别降低了50%和65%。总体而言,我们的新型转基因小鼠模型提供了一种快速实时的方法来评估和筛选潜在的NS3/4A蛋白酶抑制剂。